Moberg Pharma, Stockholm, has entered into an agreement with RoundTable Healthcare Partners and Signet Healthcare Partners to divest its entire OTC operation—which includes topical treatments like Kerasal Nail, Dermoplast and New Skin—in deal that includes a cash consideration of $155 million plus an additional consideration of $5 million. In the most recent fiscal year, Kerasal Nail recorded its third consecutive year of double-digit growth in the US and in 2018 became ranked as the No. 1 in...